August 4, 2015

Potent Compound Suite for Small Molecule Oncologicals

Regis Technologies is announcing their entry into the oncology market with the start up of the new Potent Compound Suite (PCS). The PCS allows Regis, a Chicago-based contract manufacturing organization (CMO), to target small molecule oncologicals and linker payload projects for antibody drug conjugates. Regis is a CMO operating a […]
May 8, 2015

Containment Performance Verification of the Potent Compound Suite Using Surrogate Monitoring

As part of commissioning of the Regis’ Potent Compound Suite 1 (PCS1), an industrial hygiene monitoring was performed by Safebridge Consultants, Inc., on March 4 and 5 of 2015 with the purpose to evaluate the containment performance of the facility. Based on the occupational exposure limits (OELs) of the future […]
March 6, 2015

Surrogate Powder Testing on Potent Compound Suite 1

With almost two years of planning and construction complete, Regis Technologies’ Potent Compound Suite 1 (PCS1) is in testing. On March 4th and 5th, an expert independent lab, Safebridge Consultants, Inc., performed a surrogate powder study on PCS1, in order to evaluate the containment capability of the suite and to […]
February 26, 2015

Regis Looks to Extend cGMP Services to the Oncology Market

Regis Technologies announced new potent compound capabilities this month for the development of oncology drug substances. Regis Technologies is proud to announce the commissioning and start up of their new Potent Compound Suite (PCS) for 2015. Regis is a contract manufacturing organization operating a 36,000 square foot, cGMP facility in […]
October 8, 2014

Potent Compound Initiative Underway

Regis’ Potent Compound Initiative is proceeding along well. Our Analytical Team underwent training last week on how to handle potent compounds with OEL’s (occupational exposure limit) down to 0.05 micrograms/m3 safely in the analytical labs. The Potent Compound Suite is expected to be commissioned at the end of the year, […]
January 21, 2014

Regis Technologies Reports Successful FDA Audit with no Form 483 Observations

—Two Most Recent FDA Audits had no Form 483’s, Highlighting Consistency of Regis’ Quality and Regulatory Excellence— —FDA Has Recognized Regis as a Control Testing Lab, Easing Inspection Requirements for Customers— —Visit Booth #1246 at InformEx to Learn More about Regis’ Quality Services— Morton Grove, IL, January 21, 2014 – […]